Potent inhibitors of secretory phospholipase A2: synthesis and inhibitory activities of indolizine and indene derivatives. 1996

S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
Shiongi Research Laboratories, Shionogi & Co., Ltd, Osaka, Japan.

Phospholipase A2 is an enzyme which hydrolyzes the sn-2 position of certain cellular phospholipids. The liberated lysophospholipid and arachidonic acid are precursors in the biosynthesis of various biologically active products. As human nonpancreatic sPLA2 is present in high levels in the blood of patients in several pathological conditions, the potent sPLA2 inhibitors have been suggested to be useful drugs. Here we describe the synthesis, structure-activity relationship, and inhibitory activities of indolizine and indene derivatives. 1-(Carbamoylmethyl)indolizine derivatives and 1-oxamoylindolizine derivatives exhibited very potent inhibitory activity. The former was unstable to air oxidation, but the latter exhibited an improvement both in stability and in potency. Some compounds approached the stoichiometric limit of the chromogenic assay.

UI MeSH Term Description Entries
D007192 Indenes A family of fused-ring hydrocarbons isolated from coal tar that act as intermediates in various chemical reactions and are used in the production of coumarone-indene resins.
D007212 Indolizines
D008745 Methylation Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed) Methylations
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010741 Phospholipases A Phospholipases that hydrolyze one of the acyl groups of phosphoglycerides or glycerophosphatidates.
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D000478 Alkylation The covalent bonding of an alkyl group to an organic compound. It can occur by a simple addition reaction or by substitution of another functional group. Alkylations
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
April 1998, Journal of biochemistry,
S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
January 1993, Agents and actions,
S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
December 1996, Journal of medicinal chemistry,
S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
September 2020, Expert opinion on therapeutic patents,
S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
April 2016, European journal of medicinal chemistry,
S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
January 2005, Current medicinal chemistry,
S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
January 2007, Current topics in medicinal chemistry,
S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
May 2006, Bioorganic & medicinal chemistry letters,
S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
January 1998, Pharmaceutical biotechnology,
S Hagishita, and M Yamada, and K Shirahase, and T Okada, and Y Murakami, and Y Ito, and T Matsuura, and M Wada, and T Kato, and M Ueno, and Y Chikazawa, and K Yamada, and T Ono, and I Teshirogi, and M Ohtani
July 2002, The Biochemical journal,
Copied contents to your clipboard!